2016 - Cancer Currents Blog
-
Findings from a new study from NCI researchers could help predict whether a tumor will respond to a new class of promising cancer drugs, and identifies a potential way to overcome that resistance.
-
A new study has identified a potentially critical vulnerability in lung cancers that have mutations in the KRAS gene, and showed that a drug already under study may be able to exploit it.
-
Studies in cells and mice found that, in cells with damaged DNA, a noncoding RNA called DINO stabilizes the p53 protein and guides the cells into cell death, preventing tumor development.
-
Researchers have developed an immunotherapy approach that uses immune cells whose natural cancer killing abilities have been enhanced in the lab. In a small clinical trial, the treatment led to remissions in about half of patients with acute myeloid leukemia.
-
Researchers have found that cancer cells can use the compound lactate to fuel biochemical reactions and to generate other compounds they need for growth and survival.
-
The recently launched COMET study will examine whether educating patients with cancer about genetic testing will increase their knowledge and reduce their stress levels after receiving genomic testing results.
-
In a phase II clinical trial, some patients with metastatic Merkel cell carcinoma whose cancer has progressed despite treatment with chemotherapy had durable tumor responses to the immunotherapy drug avelumab.
-
A randomized clinical trial has found that patients who received palliative care along with standard treatment for advanced cancer reported having a better quality of life and mood than patients who did not receive early palliative care.